Information about Moxphaze | 10X10 Tablets

Moxphaze Tablets stand out as a reliable solution for a range of respiratory and bacterial infections, including respiratory tract infections (RTIs), acute otitis media, pneumonia, pharyngitis, and skin and soft tissue infections (SSTI). This medication provides extensive coverage against both gram-positive and gram-negative pathogens, making it a versatile option in combating various types of infections. Moxphaze Tablets exhibit high activity against key bacteria such as staphylococci, E. coli, H. influenzae, and S. pneumoniae. Particularly notable is its designation as the first choice in treating community-acquired pneumonia (CAP), emphasizing its efficacy in respiratory infections.

The tablets offer a superior bactericidal effect, ensuring a more potent response against infectious agents. With its combination of better efficacy and tolerability, Moxphaze Tablets emerge as a preferred choice for individuals seeking effective and well-tolerated treatment for a spectrum of respiratory and bacterial infections.

Key Benefits:

In RTI’s, Acute Otitis Media, Pneumonia, Pharyngitis and SSTI

• Offers wide coverage against gram-positive and negative pathogens.
• Highly active against staphylococci, E.coli, H.influenzae, and S. pneumoniae.
• First choice in CAP.
• Better bactericidal effect.
• Better Efficacy & Tolerability.

Specification

• Type: Tablets
• Material: Amoxycillin 500mg + Potassium Clavulanate 125mg